Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Fusion protein or fusion polypeptide
Reexamination Certificate
2006-08-22
2006-08-22
Stucker, Jeffrey (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Fusion protein or fusion polypeptide
C424S188100, C424S208100, C424S192100, C435S235100, C435S320100, C536S023720, C514S04400A, C530S826000
Reexamination Certificate
active
07094408
ABSTRACT:
This invention relates to improved methods of inducing an immune response for the prevention or treatment of HIV-1 infection by using a nucleic acid vaccine in conjunction with a recombinant viral vaccine, e.g., a poxvirus vaccine, to potentiate and broaden the immune response. The present invention further provides a particularly effective vaccine regimen comprising a DNA vaccine used in combination with a poxvirus virus, especially NYVAC or ALVAC.
REFERENCES:
patent: 4235871 (1980-11-01), Papahadjopoulos et al.
patent: 4501728 (1985-02-01), Geho et al.
patent: 4603112 (1986-07-01), Paoletti et al.
patent: 4722848 (1988-02-01), Paoletti et al.
patent: 4769330 (1988-09-01), Paoletti et al.
patent: 4837028 (1989-06-01), Allen
patent: 5019369 (1991-05-01), Presant et al.
patent: 5110587 (1992-05-01), Paoletti et al.
patent: 5174993 (1992-12-01), Pailetti
patent: 5187074 (1993-02-01), Treiber et al.
patent: 5192668 (1993-03-01), Treiber et al.
patent: 5204253 (1993-04-01), Sanford et al.
patent: 5279833 (1994-01-01), Rose
patent: 5308854 (1994-05-01), Hoffman, Jr. et al.
patent: 5413999 (1995-05-01), Vacca et al.
patent: 5476874 (1995-12-01), Hungate et al.
patent: 5502060 (1996-03-01), Thompson et al.
patent: 5578597 (1996-11-01), Spector et al.
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5589466 (1996-12-01), Felgner et al.
patent: 5663169 (1997-09-01), Young et al.
patent: 5679647 (1997-10-01), Carson et al.
patent: 5703055 (1997-12-01), Felgner et al.
patent: 5714374 (1998-02-01), Arnold et al.
patent: 5736524 (1998-04-01), Content et al.
patent: 5739118 (1998-04-01), Carrano et al.
patent: 5804566 (1998-09-01), Carson et al.
patent: 5846978 (1998-12-01), Coburn et al.
patent: 5863542 (1999-01-01), Paoletti et al.
patent: 5922687 (1999-07-01), Mann et al.
patent: WO-98/04720 (1998-02-01), None
patent: WO-98/56919 (1998-12-01), None
patent: WO-01/82964 (2001-11-01), None
Riffkin et al. “A single amino-acid change between the antigenically different extracellular serine proteases V2 and B2 fromDichelobacter nodosus”, Gene, vol. 167 (1995), pp. 279-283.
Abaza et al. “Effects of amino acid substitutions outside an antigenic site on protein binding to monoclonal antibodies of predetermined specificity obtained by peptide immunization”, Journal of Protein Chemistry, vol. 11, No. 5 (1992), pp 433-444.
Cruse et al. Illustrated Dictionary of Immunology (Boca Raton, FL, CRC Press, Inc., 1995), p. 309. QR180.4.C78.
Paul, Fundamental Immunology, (Philadelphia & New York, Lippincott-Raven Publishers, 1993), pp. 250 and 1311-1312. QR181.F84.
Cohen et al. APronounced acute immunosuppression in vivo mediated by HIV Tat challenge@, Proceedings of the National Academy of Sciences of the United States of America, vol. 96, Issue 19(Sep. 14, 1999), pp. 10842□10847.
Mooij et al. “Rational development of prophylactic HIV vaccines based on structural and regulatory proteins” Vaccine, vol. 20, Issues 3-4, (Nov. 12, 2001) pp. 304-321.
Kohler et al.“No hope for an AIDS vaccine soon” AIDScience vol. 2, No. 5 (Mar. 2002), 3 pages, no page Nos.
PCT International Search Report in related application PCT/US 01/13968, (Oct. 6, 2001),6 Pages.
“Results from EV01 HIV Vaccine Trial, London and Lausanne, Jun. 7th, 2004”, (EuroVac Press Release),(Jun., 2004),2 Pages.
Abimiku, A. G., et al., “Long-Term Survival of SIVMac251—Infected Macaques Previously Immunized with NYVAC-SIV Vaccines”,Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 15(Supp 1), (1997),S78-S85.
AIDS Vaccine Advocacy Coalition, “Support for the RV144 HIV vaccine trial”,Science, 305(5681), (Jul. 9, 2004),177-80 Belshe et al.
Altman, J. D., et al., “Formation of Functional Peptide Complexes of Class II Major Histocompatibility Complex Proteins From Subunits Produced inEscherichia coli”, Pro. Natl. Acad. Sci. USA, 90, (1993), 10330-10334.
Altman, J. D., et al., “Phenotypic Analysis of Antigen-Specific T Lymphocytes”,Science, 274, (1996),94-96.
Arp, J. , et al., “Human Immunodeficiency Virus Type 1 Envelope-Specific Cytotox T Lymphocytes Response Dynamics After Prime-Boost Vaccine Regimens With Human Immunodeficiency Virus Type 1 CanaryPox and Pseudovirions”,Viral Immunology, 12(4), (Abstract Only),(1999),1 Page.
Barnett, S. W., et al., “Prime-Boost Immunization Strategies against HIV”,AIDS Research and Human Retroviruses, 14, Supp. 3, (1998),S-299-S-309.
Benson, J. , et al., “Recombinant Vaccine-Induced Protection Against the Highly Pathogenic Simian Immunodeficiency Virus SIVmac251: Dependence on Route of Challenge Exposure”,Journal of Virology, 72(5), (1998),4170-4182.
Burton, D R., et al., “Public Health. A Sound Rationale Needed for Phase III HIV-1 Vaccine Trials”,Science, 303(5656), (2004), 316.
Carpenter, C. , et al., “Report of the NIH Panel to Define Principles of Therary of HIV Infection”,Morbidity and Mortality Weekly Report, 47(RR-5), (Apr. 24, 1998),1-41.
Carroll, M. W., et al., “Host Range and Cytopathogenicity of the Highly Attenuated MVA Strain of Vaccinia Virus: Progagation and Generation of Recombinant Viruses in a Nonhuman Mammalian Cell Line”,Virology, 238(2), (1997),198-211.
Donnelly, J. J., et al., “DNA Vaccines”,Annu. Rev. Immunol., 15, (1997),617-648.
Dunbar, P. R., et al., “Direct Isolation, Phenotyping and Cloning of Low-Frequency Antigen-Specific Cytotoxic T Lymphocytes from Peripheral Blood”,Current Biology, 8, (1998),413-416.
Eloit, M. , et al., “Construction of a Defective Adenovirus Vector Expressing the Pseudorabies Virus Glycoprotein gp50 and its Use as a Live Vaccine”,Journal of General Virology, 71, (1990),2425-2431.
Felgner, P. L., et al., “Lipofection: A Highly Efficient, Lipid-Mediated DNA-Transfection Procedure”,Proc. Natl. Acad. Sci., USA, vol. 84, (1987),7413-7417.
Fuller, D. H., et al., “Enhancement of immunodeficiency virus-specific immune responses in DNA-immunized rhesus macaques”,Vaccine, 15(8), (1997),924-926.
Girard, M. , et al., “New prospects for the development of a vaccine against human immunodeficiency virus type 1. An overview”,C. R. Acad. Sci. Paris de la vie/Life Sciences, 322, (1999),959-966.
Girard, M. , et al., “New Prospects for the Development of a Vaccine Against Human Immunodeficiency Virus Type 1. An Overview”,C. R. Acad. Sci. Paris, Sciences de la vie / Life Sciences, 322, (1999),959-966.
Hanke, T. , et al., “Effective Induction of HIV-Specific CTL by Multi-Epitope Using Gene Gun in a Combined Vaccination Regime”,Vaccine, 17(6), (1999),589-596.
Hanke, T. , et al., “Effective Induction of Simian Immunodeficiency Virus-Specific Cytotoxic T Lymphoctyes in Macaques by Using a Multiepitope Gene and DNA Prime-Modified Vaccinia Virus Ankara Boost Vaccination Regimen”,Journal of Virology, 73(9), (1999),7524-7532.
Hanke, T. , et al., “Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime”,Vaccine, 16(5), (1998),439-445.
Hanke, T. , et al., “Pre-clinical development of a multi-CTL epitope-based DNA prime MVA boost vaccine for AIDS”,Immunology Letters, 66, (1999),177-181.
Kent, S. J., et al., “Enchanced T-Cell Immunogenicity and Protective Efficacy of a Human Immunodeficiency Virus Type 1 Vaccine Regimen Consisting of Consecutive Priming with DNA and Boosting with Recombinant Fowlpox Virus”,Journal of Virology, 72(12), (1998),10180-10188.
Lalvani, A. , et al., “Rapid Effector Function in CD8+ Memory T Cells”,J. Exp. Med., 186(6), (1997),859-869.
Lu, S. , et al., “Simian Immunodeficiency Virus DNA Vaccine Trial in Macaques”,Journal of Virology, 70(6), (1996),3978-3991.
Mäkitalo, B , et al., “Enhanced cellular immunity and systemic control of SHIV infection by combined parentera
Franchini Genoveffa
Hel Zdenek
Pavlakis George
Schwegman Lundberg Woessner & Kluth P.A.
Stucker Jeffrey
The United States of America as represented by the Department of
LandOfFree
Immunogenicity using a combination of DNA and vaccinia virus... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunogenicity using a combination of DNA and vaccinia virus..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunogenicity using a combination of DNA and vaccinia virus... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3615232